keyword
MENU ▼
Read by QxMD icon Read
search

Akathisia

keyword
https://www.readbyqxmd.com/read/29141124/the-effects-of-valbenazine-in-participants-with-tardive-dyskinesia-results-of-the-1-year-kinect-3-extension-study
#1
Stewart A Factor, Gary Remington, Cynthia L Comella, Christoph U Correll, Joshua Burke, Roland Jimenez, Grace S Liang, Christopher F O'Brien
BACKGROUND: Valbenazine, a highly selective vesicular monoamine transporter 2 inhibitor, is approved for the treatment of tardive dyskinesia. This is the first report of long-term effects in adults with tardive dyskinesia. METHODS: Participants with a DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or a mood disorder who completed the 6-week, double-blind, placebo-controlled period of KINECT 3 were eligible to enter the 42-week valbenazine extension (VE) period and subsequent 4-week washout period...
November 14, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29059134/aripiprazole-for-post-traumatic-stress-disorder-a-systematic-review
#2
Sara R Britnell, Anna D Jackson, Jamie N Brown, Bruce P Capehart
OBJECTIVE: The aim of this study was to review the safety and efficacy of aripiprazole as monotherapy and adjunct therapy for the treatment of post-traumatic stress disorder (PTSD). METHODS: A search of both MEDLINE (1956 to May 2017) and EMBASE (1957 to May 2017) was conducted using the terms "aripiprazole" and "post-traumatic stress disorder," "posttraumatic stress disorder," or "PTSD." Studies evaluating the primary endpoint of PTSD in patients taking aripiprazole as monotherapy or adjunct therapy were analyzed for relevance...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29046364/randomized-study-of-iv-prochlorperazine-plus-diphenhydramine-vs-iv-hydromorphone-for-migraine
#3
Benjamin W Friedman, Eddie Irizarry, Clemencia Solorzano, Alexander Latev, Karolyn Rosa, Eleftheria Zias, David R Vinson, Polly E Bijur, E John Gallagher
OBJECTIVE: To determine outcomes among patients with migraine in the emergency department (ED) who receive IV hydromorphone vs IV prochlorperazine + diphenhydramine. METHODS: This study was conducted in 2 EDs in New York City. Patients who met international criteria for migraine were eligible for participation if they had not used an opioid within the previous month. Clinicians, participants, investigators, and research personnel were blinded to treatment. Patients were randomized in blocks of 4...
October 18, 2017: Neurology
https://www.readbyqxmd.com/read/29017334/brexpiprazole-a-new-leaf-on-the-partial-dopamine-agonist-branch
#4
Judy Hope, David Castle, Nicholas A Keks
OBJECTIVES: Brexpiprazole is a new dopamine partial agonist antipsychotic in the same class as aripiprazole. This paper will briefly review brexpiprazole and compare it with aripiprazole. CONCLUSIONS: Brexpiprazole and aripiprazole are both partial agonists at dopamine D2, and serotonin 5-HT1A and antagonists at serotonin 5-HT2A and noradrenergic α1B receptors. However, the two drugs are significantly different in potencies at various receptors; neurochemical profiles predict that brexpiprazole may be comparable with aripiprazole in its antipsychotic efficacy but may cause less akathisia, extrapyramidal side effects (EPS) and activation...
October 1, 2017: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/28952832/prevalence-and-pattern-of-antipsychotic-induced-movement-disorders-in-a-tertiary-care-teaching-hospital-in-india-a-cross-sectional-study
#5
Nimisha Desai, Parvati B Patel, Sandip Shah, Tejas K Patel, Saurabh N Shah, Ela Vatsala
OBJECTIVES: To assess prevalence and pattern of movement disorders among patients taking antipsychotic medications. METHODS: This cross-sectional, intensive monitoring (patient interview, case record form review and clinical examination) study was conducted in patients taking antipsychotic drugs irrespective of duration for the development of movement disorders. The psychiatrist used Modified Simpson-Angus Scale score (10-item scale), Barnes' rating scale and Abnormal Involuntary Movement Scale to diagnose parkinsonism, akathisia and tardive dyskinesia, respectively...
September 27, 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/28946761/randomized-double-blind-placebo-controlled-trial-of-asenapine-maintenance-therapy-in-adults-with-an-acute-manic-or-mixed-episode-associated-with-bipolar-i-disorder
#6
Armin Szegedi, Suresh Durgam, Mary Mackle, Sung Yun Yu, Xiao Wu, Maju Mathews, Ronald P Landbloom
OBJECTIVE: The authors determined the efficacy and safety of asenapine in preventing recurrence of any mood episode in adults with bipolar I disorder. METHOD: Adults with an acute manic or mixed episode per DSM-IV-TR criteria were enrolled in this randomized, placebo-controlled trial consisting of an initial 12- to 16-week open-label period and a 26-week double-blind randomized withdrawal period. The target asenapine dosage was 10 mg b.i.d. in the open-label period but could be titrated down to 5 mg b...
September 26, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28941779/historical-and-conceptual-aspects-of-motor-disorders-in-the-psychoses
#7
German E Berrios, Ivana S Marková
Historical epistemology is a useful method to understand the longitudinal construction of the movement disorders in psychiatry. Four periods can be identified in such a process. The first, extending from Classical times to the work of Griesinger, included disorders such as catalepsy, crocidism, epilepsy and paralysis. The second period, stretching from Griesinger to Kahlbaum, concentrated on the study of melancholia attonita, stupor and catatonia. The third period, covering the time from Kahlbaum to WWI, witnessed important conceptual shifts such as: the transformation of madness into psychoses; the redefinition of movement and motility in psychiatry; the appearance of self-contained syndromes as dyskinesias, tics, akathisia, complex disorders like the cases of encephalitis lethargica, etc...
September 20, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28940256/chlorpromazine-versus-penfluridol-for-schizophrenia
#8
REVIEW
Naemeh Nikvarz, Mostafa Vahedian, Navid Khalili
BACKGROUND: The efficacy of chlorpromazine, a benchmark antipsychotic, has not been fully assessed in direct comparison with different individual antipsychotics. Penfluridol is another old antipsychotic with a long half-life so one oral dose may last up to one week. This could confer advantage. OBJECTIVES: To assess the clinical effects of chlorpromazine compared with penfluridol for adults with schizophrenia. SEARCH METHODS: On 31 March 2017, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO, and registries of clinical trials...
September 23, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28902525/lurasidone-efficacy-and-safety-in-the-treatment-of-psychotic-and-mood-disorders
#9
Maurizio Pompili, Claudio Verzura, Giada Trovini, Andrea Buscajoni, Giulia Falcone, Stefano Naim, Adele Nardella, Serena Sorice, Ross J Baldessarini, Paolo Girardi
Lurasidone ([3aR,4S,7R,7aS]-2-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1yl-methyl] cyclohexylmethyl]-hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; Latuda® [LRSD]) is a novel benzisothiazole, second-generation antipsychotic drug developed by Dainippon Sumitomo Pharma Corporation in Japan. Similar to other atypical antipsychotics it has a distinctive pharmacodynamic profile, Areas covered: This review updates reported research findings on the efficacy, safety and tolerability of LRSD for treatment of psychotic and major affective disorders, with meta-analyses...
September 13, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28890132/motor-abnormalities-in-first-episode-psychosis-patients-and-long-term-psychosocial-functioning
#10
Manuel J Cuesta, Elena García de Jalón, M Sol Campos, Lucía Moreno-Izco, Ruth Lorente-Omeñaca, Ana M Sánchez-Torres, Víctor Peralta
Motor abnormalities (MAs) are highly prevalent in patients with first-episode psychosis both before any exposure and after treatment with antipsychotic drugs. However, the extent to which these abnormalities have predictive value for long-term psychosocial functioning is unknown. One hundred antipsychotic-naive first-episode psychosis (FEP) patients underwent extensive motor evaluation including catatonic, parkinsonism, dyskinesia, akathisia and neurological soft signs. Patients were assessed at naïve state and 6months later...
September 7, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28843918/the-safety-and-tolerability-of-cariprazine-in-patients-with-manic-or-mixed-episodes-associated-with-bipolar-i-disorder-a-16-week-open-label-study
#11
Terence A Ketter, Gary S Sachs, Suresh Durgam, Kaifeng Lu, Anju Starace, István Laszlovszky, György Németh
BACKGROUND: We evaluated the safety/tolerability of longer-term open-label treatment with cariprazine in patients who had responded to cariprazine for acute bipolar mania. METHODS: In this multinational, multicenter study, open-label, flexible-dose, cariprazine 3-12mg/d was administered for up to 16 weeks to patients (18-65 years) with bipolar mania. Safety evaluations included adverse events (AEs), laboratory values, vital signs, and extrapyramidal symptom (EPS) scales...
January 1, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28839337/a-phase-1-study-comparing-pharmacokinetic-and-safety-profiles-of-three-different-dose-intervals-of-aripiprazole-lauroxil
#12
Robert Risinger, Marjie Hard, Peter J Weiden
BACKGROUND: Aripiprazole lauroxil (AL) is an FDA-approved treatment for schizophrenia. AL is a non-ester prodrug of aripiprazole that results in extended systemic release of aripiprazole after intramuscular (IM) administration. This Phase-1 study evaluated the pharmacokinetics (PK) and safety of a new AL dose (1064 mg)* for 2-month dose intervals. The study also evaluated 4- and 6-week dose intervals of AL at the 441 mg and 882 mg doses, respectively. METHODS: A total of 139 patients diagnosed with schizophrenia and stabilized on a first-line antipsychotic (other than aripiprazole) were randomized to one of 3 dose/dose-interval groups: a 4-week interval of AL 441 mg (n = 35), a 6-week interval of AL 882 mg (n = 34), and an 8-week interval of AL 1064 mg IM injection (n = 70)...
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28836957/the-safety-and-tolerability-of-cariprazine-in-long-term-treatment-of-schizophrenia-a-post-hoc-pooled-analysis
#13
Henry A Nasrallah, Willie Earley, Andrew J Cutler, Yao Wang, Kaifeng Lu, István Laszlovszky, György Németh, Suresh Durgam
BACKGROUND: Schizophrenia is a chronic and debilitating neuropsychiatric disorder that often requires long-term pharmacotherapy to manage symptoms and prevent relapse. Cariprazine is a potent dopamine D3 and D2 receptor partial agonist that is FDA-approved in the US for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults; the recommended dose range is 1.5-6 mg/d. METHODS: To further characterize the long-term safety of cariprazine, data from two 48-week open-label, flexible-dose extension studies were pooled for post hoc analyses...
August 24, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28817397/real-world-data-on-paliperidone-palmitate-for-the-treatment-of-schizophrenia-and-other-psychotic-disorders-a-systematic-review-of-randomized-and-nonrandomized-studies
#14
Robin Emsley, Eduard Parellada, Miquel Bioque, Berta Herrera, Teresa Hernando, Marta García-Dorado
The aim of this study was to perform a systematic review of the effects of 1-month paliperidone palmitate (PP1M) for the treatment of schizophrenia and related psychotic disorders in terms of outcomes reported in real-world evidence studies. A systematic review of real-world randomized and nonrandomized studies with PP1M was performed and is reported according to PRISMA guidelines. Comparative effectiveness data with oral antipsychotics indicate that PP1M has a lower likelihood of relapse-related events, including rehospitalization, and these differences are clinically relevant...
August 16, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28814873/safety-and-efficacy-of-paliperidone-palmitate-1-month-formulation-in-chinese-patients-with-schizophrenia-a-25-week-open-label-multicenter-phase-iv-study
#15
Jingping Zhao, Lehua Li, Jianguo Shi, Yi Li, Xiufeng Xu, Keqing Li, Lili Zhang, Shangli Cai, Yu Feng, Jianmin Zhuo, Weihong Liu, Huafei Lu
RATIONALE: Long-acting injectable (LAI) paliperidone palmitate 1-month formulation (PP1M) has demonstrated acceptable tolerability and favorable clinical outcomes in Western and Asian patients with schizophrenia. Hence, analysis of the outcomes of long-term PP1M treatment specifically in Chinese patients is of interest. OBJECTIVE: The aim of this study is to evaluate the long-term safety and efficacy of PP1M treatment in Chinese patients with schizophrenia. METHODS: In this 25-week, open-label, Phase IV study, patients (18-65 years) diagnosed with schizophrenia and having a baseline Positive and Negative Syndrome Scale (PANSS) total score of 60-120 (inclusive) were enrolled...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28808283/drug-induced-extrapyramidal-symptoms-scale-diepss-serbian-language-version-inter-rater-and-test-retest-reliability
#16
Ami Peljto, Ljubica Zamurovic, Milica Pejovic Milovancevic, Branko Aleksic, Dusica Lecic Tosevski, Toshiya Inada
Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) is developed in the era of second-generation antipsychotics and is suitable for evaluation of the low incidence of extrapyramidal symptoms occurring in the treatment of atypical antipsychotics, as well as the relationship between personal and social functioning. The study was carried out at the Institute of Mental Health in Serbia in 2015 Study used the 127 DIEPSS video clips material, recorded from 1987 till 2015. Four raters performed the assessment simultaneously, individually rating one assigned item immediately after seeing the video clip...
August 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28802674/the-yusuf-peto-method-was-not-a-robust-method-for-meta-analyses-of-rare-events-data-from-antidepressant-trials
#17
Tarang Sharma, Peter C Gøtzsche, Oliver Kuss
OBJECTIVE: To identify the validity of effect estimates for serious rare adverse events in clinical study reports of antidepressants trials, across different meta-analysis methods. STUDY DESIGN AND SETTING: Four serious rare adverse events (all-cause mortality, suicidality, aggressive behaviour and akathisia) were meta-analysed using different methods. The Yusuf-Peto odds ignores studies with no events, was compared with the alternative approaches of generalised linear mixed models (GLMM), conditional logistic regression, a Bayesian approach using Markov Chain Monte Carlo (MCMC) and a beta-binomial regression model...
August 9, 2017: Journal of Clinical Epidemiology
https://www.readbyqxmd.com/read/28775195/movement-side-effects-of-antipsychotic-drugs-in-adults-with-and-without-intellectual-disability-uk-population-based-cohort-study
#18
Rory Sheehan, Laura Horsfall, André Strydom, David Osborn, Kate Walters, Angela Hassiotis
OBJECTIVES: To measure the incidence of movement side effects of antipsychotic drugs in adults with intellectual disability and compare rates with adults without intellectual disability. DESIGN: Cohort study using data from The Health Improvement Network. SETTING: UK primary care. PARTICIPANTS: Adults with intellectual disability prescribed antipsychotic drugs matched to a control group of adults without intellectual disability prescribed antipsychotic drugs...
August 3, 2017: BMJ Open
https://www.readbyqxmd.com/read/28741044/efficacy-and-tolerability-of-asenapine-compared-with-olanzapine-in-borderline-personality-disorder-an-open-label-randomized-controlled-trial
#19
Paola Bozzatello, Paola Rocca, Maria Uscinska, Silvio Bellino
BACKGROUND: Asenapine is a new second-generation antipsychotic that is understudied in borderline personality disorder (BPD). Only one study investigating the use of the drug in this indication (an open-label pilot study) has been conducted to date. OBJECTIVE: The present open-label, randomized, controlled trial aimed to evaluate the efficacy and tolerability of asenapine in comparison with olanzapine, the most broadly studied antipsychotic in BPD. METHODS: A total of 51 outpatients aged between 18 and 50 years with a diagnosis of BPD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria were assigned for 12 weeks to asenapine (5-10 mg/day) or olanzapine (5-10 mg/day)...
September 2017: CNS Drugs
https://www.readbyqxmd.com/read/28736102/antipsychotic-drugs-for-the-acute-treatment-of-patients-with-a-first-episode-of-schizophrenia-a-systematic-review-with-pairwise-and-network-meta-analyses
#20
Yikang Zhu, Marc Krause, Maximilian Huhn, Philipp Rothe, Johannes Schneider-Thoma, Anna Chaimani, Chunbo Li, John M Davis, Stefan Leucht
BACKGROUND: The first episode of schizophrenia is a pivotal phase of this debilitating illness. Which drug to use remains controversial without a summary of all direct or indirect comparisons of drugs. We did a systematic review with pairwise and network meta-analyses of efficacy and tolerability. METHODS: We searched MEDLINE, Embase, PsycINFO, Cochrane Library, PubMed, Biosis, and ClinicalTrials.gov for randomised controlled trials of antipsychotics for the acute treatment of first-episode schizophrenia, published up to Nov 17, 2016...
July 20, 2017: Lancet Psychiatry
keyword
keyword
13829
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"